Sex-differential effects of olanzapine vs. aripiprazole on glucose and lipid metabolism in first-episode schizophrenia
Objective: To compare sex difference in metabolic effect of olanzapine versus aripiprazole on schizophrenia. Methods: A twelve-week prospective open-label cohort study to compare four subgroups according to first-episode schizophrenia patients’ type of drug usage and sex: female aripiprazole (n = 11...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | Brasil |
| Institución: | Universidade de São Paulo (USP) |
| Repositorio: | Archives of Clinical Psychiatry |
| Idioma: | inglés |
| OAI Identifier: | oai:revistas.usp.br:article/162168 |
| Acceso en línea: | https://revistas.usp.br/acp/article/view/162168 |
| Access Level: | acceso abierto |
| Palabra clave: | Schizophrenia sex difference glucose and lipid olanzapine aripiprazole |
| Sumario: | Objective: To compare sex difference in metabolic effect of olanzapine versus aripiprazole on schizophrenia. Methods: A twelve-week prospective open-label cohort study to compare four subgroups according to first-episode schizophrenia patients’ type of drug usage and sex: female aripiprazole (n = 11), male aripiprazole (n = 11), female olanzapine (n = 10), and male olanzapine (n = 11) for body mass index, fasting serum triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and fasting glucose. Results: Aripiprazole may be associated with weight gain in female patients with low-baseline weight. Aripiprazole may have an adverse effect of weight and favorable effects of circulating glucose and lipid on female over male schizophrenia patients. The aripiprazole–induced changes in glucose and lipid may be independent of body fat storage, especially for female schizophrenia patients. Olanzapine may have adverse effects of weight, glucose and lipid profiles on female over male schizophrenic patients. Discussion: Our findings fill the gap in knowledge and provide a sex-specific guidance to psychiatrist better tailoring treatment to individual sex-differential characteristics and a key clue to understand the sex-differential mechanism of antipsychotics-induced metabolic dysfunction. |
|---|